Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes

Diana Campioni, Paola Secchiero, Federica Corallini, Elisabetta Melloni, Silvano Capitani, Francesco Lanza, Giorgio Zauli

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Myelodysplastic syndromes (MDS) are characterized by impaired erythropoiesis, possibly caused by proapoptotic cytokines. We focused our study on the cytokiue TRAIL (TNF-related apoptosis-inducing ligand), which has been shown to exhibit an anti-differentiation activity on erythroid maturation. Immunocytochetnical analysis of bone marrow mononuclear cells (BMMC) showed an increased expression of TRAIL in MDS patients with respect to acute myeloid leukemia (AML) patients and normal BM donors. TRAIL expression was increased predominantly in myeloid precursors of granulocytic lineage and in a subset of monocytes and pro-erythroblasts. Significant levels of soluble TRAIL were released in 21 of 68 BMMC culture supernatants from MDS patients. On the other hand, TRAIL was detected less frequently in the culture supernatants of AML (4 of 33) and normal BMMC (0 of 22). Analysis of peripheral blood parameters revealed significantly lower levels of peripheral red blood cells and hemoglobin in the subset of patients whose BMMC released TRAIL in culture supernatants compared to the subgroup of patients who did not release TRAIL. Moreover, TRAIL-positive BMMC culture supernatants inhibited the differentiation of normal glycophorin A+ erythroblasts generated in serum-free liquid phase. Thus, increased expression and release of TRAIL at the bone marrow level is likely to impair erythropoiesis and to contribute to the degree of anemia, the major clinical feature of MDS.

Original languageEnglish
Pages (from-to)557-563
Number of pages7
JournalAmerican Journal of Pathology
Volume166
Issue number2
Publication statusPublished - Feb 2005

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
Myelodysplastic Syndromes
Anemia
Bone Marrow Cells
Erythroblasts
Erythropoiesis
Acute Myeloid Leukemia
Cell Culture Techniques
Glycophorin
Monocytes
Hemoglobins
Erythrocytes
Bone Marrow
Tissue Donors
Cytokines

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Campioni, D., Secchiero, P., Corallini, F., Melloni, E., Capitani, S., Lanza, F., & Zauli, G. (2005). Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. American Journal of Pathology, 166(2), 557-563.

Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. / Campioni, Diana; Secchiero, Paola; Corallini, Federica; Melloni, Elisabetta; Capitani, Silvano; Lanza, Francesco; Zauli, Giorgio.

In: American Journal of Pathology, Vol. 166, No. 2, 02.2005, p. 557-563.

Research output: Contribution to journalArticle

Campioni, D, Secchiero, P, Corallini, F, Melloni, E, Capitani, S, Lanza, F & Zauli, G 2005, 'Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes', American Journal of Pathology, vol. 166, no. 2, pp. 557-563.
Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. American Journal of Pathology. 2005 Feb;166(2):557-563.
Campioni, Diana ; Secchiero, Paola ; Corallini, Federica ; Melloni, Elisabetta ; Capitani, Silvano ; Lanza, Francesco ; Zauli, Giorgio. / Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. In: American Journal of Pathology. 2005 ; Vol. 166, No. 2. pp. 557-563.
@article{752c201e49094d1a819ba06ee5fcf7db,
title = "Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes",
abstract = "Myelodysplastic syndromes (MDS) are characterized by impaired erythropoiesis, possibly caused by proapoptotic cytokines. We focused our study on the cytokiue TRAIL (TNF-related apoptosis-inducing ligand), which has been shown to exhibit an anti-differentiation activity on erythroid maturation. Immunocytochetnical analysis of bone marrow mononuclear cells (BMMC) showed an increased expression of TRAIL in MDS patients with respect to acute myeloid leukemia (AML) patients and normal BM donors. TRAIL expression was increased predominantly in myeloid precursors of granulocytic lineage and in a subset of monocytes and pro-erythroblasts. Significant levels of soluble TRAIL were released in 21 of 68 BMMC culture supernatants from MDS patients. On the other hand, TRAIL was detected less frequently in the culture supernatants of AML (4 of 33) and normal BMMC (0 of 22). Analysis of peripheral blood parameters revealed significantly lower levels of peripheral red blood cells and hemoglobin in the subset of patients whose BMMC released TRAIL in culture supernatants compared to the subgroup of patients who did not release TRAIL. Moreover, TRAIL-positive BMMC culture supernatants inhibited the differentiation of normal glycophorin A+ erythroblasts generated in serum-free liquid phase. Thus, increased expression and release of TRAIL at the bone marrow level is likely to impair erythropoiesis and to contribute to the degree of anemia, the major clinical feature of MDS.",
author = "Diana Campioni and Paola Secchiero and Federica Corallini and Elisabetta Melloni and Silvano Capitani and Francesco Lanza and Giorgio Zauli",
year = "2005",
month = "2",
language = "English",
volume = "166",
pages = "557--563",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes

AU - Campioni, Diana

AU - Secchiero, Paola

AU - Corallini, Federica

AU - Melloni, Elisabetta

AU - Capitani, Silvano

AU - Lanza, Francesco

AU - Zauli, Giorgio

PY - 2005/2

Y1 - 2005/2

N2 - Myelodysplastic syndromes (MDS) are characterized by impaired erythropoiesis, possibly caused by proapoptotic cytokines. We focused our study on the cytokiue TRAIL (TNF-related apoptosis-inducing ligand), which has been shown to exhibit an anti-differentiation activity on erythroid maturation. Immunocytochetnical analysis of bone marrow mononuclear cells (BMMC) showed an increased expression of TRAIL in MDS patients with respect to acute myeloid leukemia (AML) patients and normal BM donors. TRAIL expression was increased predominantly in myeloid precursors of granulocytic lineage and in a subset of monocytes and pro-erythroblasts. Significant levels of soluble TRAIL were released in 21 of 68 BMMC culture supernatants from MDS patients. On the other hand, TRAIL was detected less frequently in the culture supernatants of AML (4 of 33) and normal BMMC (0 of 22). Analysis of peripheral blood parameters revealed significantly lower levels of peripheral red blood cells and hemoglobin in the subset of patients whose BMMC released TRAIL in culture supernatants compared to the subgroup of patients who did not release TRAIL. Moreover, TRAIL-positive BMMC culture supernatants inhibited the differentiation of normal glycophorin A+ erythroblasts generated in serum-free liquid phase. Thus, increased expression and release of TRAIL at the bone marrow level is likely to impair erythropoiesis and to contribute to the degree of anemia, the major clinical feature of MDS.

AB - Myelodysplastic syndromes (MDS) are characterized by impaired erythropoiesis, possibly caused by proapoptotic cytokines. We focused our study on the cytokiue TRAIL (TNF-related apoptosis-inducing ligand), which has been shown to exhibit an anti-differentiation activity on erythroid maturation. Immunocytochetnical analysis of bone marrow mononuclear cells (BMMC) showed an increased expression of TRAIL in MDS patients with respect to acute myeloid leukemia (AML) patients and normal BM donors. TRAIL expression was increased predominantly in myeloid precursors of granulocytic lineage and in a subset of monocytes and pro-erythroblasts. Significant levels of soluble TRAIL were released in 21 of 68 BMMC culture supernatants from MDS patients. On the other hand, TRAIL was detected less frequently in the culture supernatants of AML (4 of 33) and normal BMMC (0 of 22). Analysis of peripheral blood parameters revealed significantly lower levels of peripheral red blood cells and hemoglobin in the subset of patients whose BMMC released TRAIL in culture supernatants compared to the subgroup of patients who did not release TRAIL. Moreover, TRAIL-positive BMMC culture supernatants inhibited the differentiation of normal glycophorin A+ erythroblasts generated in serum-free liquid phase. Thus, increased expression and release of TRAIL at the bone marrow level is likely to impair erythropoiesis and to contribute to the degree of anemia, the major clinical feature of MDS.

UR - http://www.scopus.com/inward/record.url?scp=13244290233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13244290233&partnerID=8YFLogxK

M3 - Article

C2 - 15681838

AN - SCOPUS:13244290233

VL - 166

SP - 557

EP - 563

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 2

ER -